Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Judith Balmaña, Peter A. Fasching, Fergus J. Couch, Suzette Delaloge, Intidhar Labidi-Galy, Joyce O’Shaughnessy, Yeon Hee Park, Andrea F. Eisen, Benoit You, Hughes Bourgeois, Anthony Gonçalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V. Timcheva, Tjoung Won Park-SimonAntonio Antón-Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A. Gelmon

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY'. Together they form a unique fingerprint.

Medicine & Life Sciences